TransMedics Group, Inc.

TransMedics Group, Inc.

TMDX·NASDAQ

$71.48

+2.6%
HealthcareMedical - Devices

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

At a Glance

Live Snapshot
Market Cap$2.47B
EPS5.6000
P/E Ratio12.76
Earnings Date07/29/2026

tmdx

Cost of Revenue

Last Annual Value

242.69M

3-Year CAGR

105%

5-Year CAGR

93%

10-Year CAGR

46%

TransMedics Group, Inc.

TransMedics Group, Inc. Competitors Analysis of Cost of Revenue

TMDX · NASDAQ
CompanyCost of Revenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
242.69M
40.5%92.8%46.2% 
0.00
N/AN/AN/A
114.23M
14.8%11.4%21.6%
1.86B
8.6%9.0%7.9%
119.64M
6.7%N/AN/A
0.00
N/AN/AN/A
246.00M
12.2%14.1%8.3%
59.00K
N/AN/AN/A
10.02B
29.2%N/AN/A
4.63B
11.7%11.7%21.3%
IMVT logo
Immunovant, Inc.
NASDAQ:IMVT
0.00
N/AN/AN/A
TransMedics Group, Inc.

TransMedics Group, Inc. Fair Value Envelope

TMDX · NASDAQ

Our analysis suggests that TMDX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $71.4764, this represents a potential HIDDEN relative to our calculated worth for TransMedics Group, Inc..

Intrinsic Value
Current Price: $71.4764